Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
*Comentado por Dra Paloma Porto Rearranjos cromossômicos envolvendo o gene do ALK (linfoma quinase anaplásico) definem
realonco
06/06/2024